Ian Hardy

Ian Hardy is an experienced pharmaceutical professional with extensive expertise in Chemistry Manufacturing and Controls (CMC). Ian currently serves as Vice President of CMC at Deerfield Management since April 2019. Previously, Ian held the position of Interim Chief Executive Officer and Chairman of the Board at Adaptive Phage Therapeutics. From March 2016 to April 2019, Ian was Vice President of CMC at Lycera, and earlier, served as CMC Director at Tetralogic Pharmaceuticals. Ian's career began at GlaxoWellcome, where development of various drug delivery systems was a focus. Ian's educational background includes an MBA from the University of Warwick, a PhD in Pharmaceutics from the University of Nottingham, and a BSc in Pharmaceutical Sciences from the University of Greenwich.